治疗难辨梭菌感染的新18元大环内酯抗生素非达霉素  

Fidaxomicin,a novel 18-membered macrolide antibiotic for the management of Clostridium difficile infection

作　　者：黄仲义[1,2] 黄嘉骅 赵永红[1,2] 

机构地区：[1]上海市静安区中心医院 [2]复旦大学附属华山医院静安分院,上海200040 [3]上海佳得旺科技咨询有限公司,上海200040

出　　处：《上海医药》2014年第1期50-54,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：难辨梭菌感染(Clostridium difficile infection,CDI)发病率正在升高,在有些国家已成为医院获得性感染主要致病菌之一。经典药物治疗是采用万古霉素和/或甲硝唑治疗,但近年随着甲硝唑耐药新突变株出现,临床对其处理日益困惑。2011年1月非达霉素获美国食品和药物管理局批准上市,为本病治疗开辟了新的治疗途径。本文就非达霉素药效学、药动学、安全性、药物相互作用以及临床应用进行了综合介绍,并对比了非达霉素与万古霉素在治疗CDI时药理作用等区别,供临床应用时参考。The morbidity associated with Clostridium difficile infection （CDI） is rising. In some countries, CDI has become one of the major pathogenic bacteria resulting in the hospital acquired infection. The classical drug therapy for CDI is the use of vancomycin and/or metronidazole. However, with emergence of the new metronidazole resistance mutants of Clostridium difficile, the clinical treatments become progressively confused. The new therapeutic approach for CDI could not be effective till fidaxomicin was approved by FDA in January 2011. This paper introduces the pharmacodynamics, pharmacokinetics, safety, drug interactions and clinical application of fidaxomicin, and the pharmacological differences between fidaxomicin and vancomycin in the treatment of CDI are compared so as to provide a reference for clinical application.

关 键 词：非达霉素 万古霉素 难辨梭菌感染 药效学药动学 

分 类 号：R978.15[医药卫生—药品]